DIRECTORS, SUPERVISORS AND SENIOR MANAGEMENT

Dr. Feng obtained his bachelor’s degree in biological sciences and technology from
Tsinghua University, PRC in July 1997 and his Ph.D. degree in molecular pharmacology from
Albert Einstein College of Medicine, the United States in September 2003. Dr. Feng was
selected to participate in the Leading Innovators Program (創新領軍人才) of Wujiang district,
the PRC in December 2014. He has published a number of academic articles and is an inventor
of a number of patents. Dr. Feng is not and has not been a director of any other listed companies
in Hong Kong or overseas in the past three years.

Mr. Zhang Zhuobing (張卓兵), aged 51, was appointed as an executive Director on
December 22, 2016 and has been a deputy general manager of our Company since May 2016.
Mr. Zhang was one of the founders of our Company when it was established in December 2012
and was a supervisor of our Company from December 2012 to March 2013. He has also been
an executive director and general manager of Suzhou Union Biopharm since October 2013.

Mr. Zhang has over 10 years of experience in the pharmaceutical industry. Mr. Zhang has
also been a director of Shanghai Union Biopharm from November 2011 to November 2015 and
a deputy general manager of Shanghai Union Biopharm from July 2008 to November 2015, the
legal representative, executive director and general manager of Suzhou Union Biopharm since
October 2013, a director of Beijing Xinjingke Biotechnology from May 2016 until June 2018
when it was transferred and a director of Beijing Tianshi since April 2016.

Mr. Zhang obtained his master’s degree in biochemistry from Tsinghua University, PRC
in July 1995. Mr. Zhang was awarded the first prize of the Shandong district award for
invention in 2005. Mr. Zhang is not and has not been a director of any other listed companies
in Hong Kong or overseas in the past three years.

Dr. Wu Hai (武海), aged 45, was appointed as an executive Director on December 22,
2016 and was also our chief science officer. Dr. Wu joined our Group in June 2013 and has
been a deputy general manager of our Company since then. Dr. Wu was the chief financial
officer of our Company from June 2013 to June 2018. He was appointed as the chief financial
officer of TopAlliance in January 2014 and was appointed as its president in August 2017. Dr.
Wu took part in the invention of certain registered patents and patents in application in relation
to JS002 and JS003 for our Group.

Dr. Wu has over 10 years of experience in the biopharmaceutical industry. Dr. Wu’s main
experience prior to joining our Group includes: from March 2003 to September 2007, he
worked as a postdoctoral res affiliate at the Stanford University; from August 2007 to February
2009, he was a scientist at Trellis Biosciences; from February 2009 to May 2013, he was a
senior scientist at Amgen.

– 262 –

